Do you face challenges when it comes to smaller production quantities, more specialization and many product creations.
Flexibility is the answer. With the help of agile systems pharmaceutical manufacturers can overcome these challenges just as easy.
Learn how flexible systems bring the decisive advantage to simply switch between the technologies of which you can benefit already in the development phase of solids. The white paper provides information on important approaches to
making solids production more flexible and how agile systems can help.
In October, FDA reorganized rare disease development around a fit-for-purpose framework and a new pathway for individualized gene editing. Regulators in Europe and the UK set out long-term plans for clinical trials, AI, and moving away from animal testing.
Clinical, manufacturing, safety, and commercial teams all lean on shared data. They need to agree on who publishes each data product, who can use it, and what evidence goes with it.
The FDA approves VOCERYQ, the first DNA medicine, for RRP surgery reduction, raising plasmid, drug-device, and confirmatory trial manufacturing demands.
The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
